Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA6 | P23280 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | NOS3 | P29474 | 2/20 | 0.50 |
| ▸ | NOS1 | P29475 | 2/20 | 0.50 |
| ▸ | NOS2 | P35228 | 2/20 | 0.50 |
| ▸ | KMO | O15229 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9676480 | 1.00 | CA12 (0.54) | CA12CA1CA2CA6CA9 | |
| SCHEMBL31045928 | 0.84 | RAB9A (0.65) | CA12CA1CA2CA6CA9 | |
| SCHEMBL69865 | 0.84 | RAB9A (0.65) | CA12CA1CA2CA6CA9 | |
| SCHEMBL69866 | 0.84 | RAB9A (0.65) | CA12CA1CA2CA6CA9 | |
| SCHEMBL5486185 | 0.81 | TRPA1 (0.67) | CA12CA1CA2CA6CA9 | |
| SCHEMBL13283358 | 0.81 | ALDH1A1 (0.47) | MAPTRAB9ANPC1SMN1; SMN2KMT2A | |
| SCHEMBL3782119 | 0.81 | CA12 (0.52) | CA12CA1CA2CA6CA9 | |
| SCHEMBL9292438 | 0.81 | NOS3 (0.57) | CA12CA1CA2CA6CA9 | |
| SCHEMBL3782123 | 0.81 | CA12 (0.52) | CA12CA1CA2CA6CA9 | |
| SCHEMBL14437429 | 0.81 | TRPA1 (0.67) | CA12CA1CA2CA6CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107880277-A | A kind of two-dimentional zinc coordination polymer and preparation method thereof | 池州学院 | 2018-04-06 | — | — | CN | claimed |
| US-20250011315-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | PRISM MEDICINES, INC. | 2025-01-09 | — | — | US | disclosed |
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | Ikena Oncology, Inc. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | Ikena Oncology, Inc. (US) | 2024-07-09 | — | — | US | disclosed |
| WO-2024041586-A1 | PRODRUG OF JAK KINASE INHIBITOR | 启元生物(杭州)有限公司 | 2024-02-29 | — | — | WO | disclosed |
| US-20230295147-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | ARYL THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295147-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | ARYL THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| CN-114345825-B | Mask cleaning method, cleaning liquid, cleaning apparatus, and method for manufacturing organic device | 大日本印刷株式会社 | 2023-08-22 | — | — | CN | disclosed |
| US-11608329-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | Ikena Oncology, Inc. (US) | 2023-03-21 | — | — | US | disclosed |
| CN-115279741-A | 4-phenyl-N- (phenyl) thiazol-2-amine derivatives and related compounds as Aryl Hydrocarbon Receptor (AHR) agonists for the treatment of, for example, angiogenesis-related disorders or inflammatory disorders | 医肯纳肿瘤学公司 | 2022-11-01 | — | — | CN | disclosed |
| US-6417178-B1 | Amyloid binding nitrogen-linked compounds for the antemortem diagnosis of alzheimer's disease, in vivo imaging and prevention of amyloid deposits | UNIVERSITY OF PITTSBURGH | 2002-07-09 | — | — | US | disclosed |
| EP-1110945-A2 | Azocompounds for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition | UNIVERSITY OF PITTSBURGH (US) | 2001-06-27 | — | — | EP | disclosed |
| WO-1999024394-A9 | COMPOUNDS FOR THE ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | UNIV PITTSBURGH (US) | 2001-05-31 | — | — | WO | disclosed |
| CN-1285818-A | Compounds for antemortem diagnosis and in vivo imaging of alzheimer's disease and prevention of amyloid deposition | UNIV PITTSBURGH (US) | 2001-02-28 | — | — | CN | disclosed |
| EP-1028941-A2 | COMPOUNDS FOR THE ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | UNIVERSITY OF PITTSBURGH (US) | 2000-08-23 | — | — | EP | disclosed |
| WO-1999024394-A2 | COMPOUNDS FOR THE ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | UNIVERSITY OF PITTSBURGH (US) | 1999-05-20 | — | — | WO | disclosed |
| CN-1189816-A | Azocompounds for the antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid depositon | UNIV PITTSBURGH (US) | 1998-08-05 | — | — | CN | disclosed |
| EP-0823894-A1 | AZOCOMPOUNDS FOR THE ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | UNIVERSITY OF PITTSBURGH (US) | 1998-02-18 | — | — | EP | disclosed |
| WO-1996034853-A1 | AZOCOMPOUNDS FOR THE ANTEMORTEM DIAGNOSIS OF ALZHEIMER'S DISEASE AND IN VIVO IMAGING AND PREVENTION OF AMYLOID DEPOSITION | UNIVERSITY OF PITTSBURGH (US) | 1996-11-07 | — | — | WO | disclosed |
| EP-0346827-A1 | Process and composition for producing protective and colour-receptive coatings on aluminium | Lea Manufacturing Company (US) | 1989-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011315-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | AHR, ARNT, HCAR1 | CA12 4196/4885CA1 4763/4885CA2 4373/4885 |
| US-11608329-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | AHR, ARNT, HCAR1 | CA12 4196/4885CA1 4763/4885CA2 4373/4885 |
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | AHR, ARNT, HCAR1 | CA12 4196/4885CA1 4763/4885CA2 4373/4885 |
| US-20230295147-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | AHR, ARNT, HCAR1 | CA12 4196/4885CA1 4763/4885CA2 4373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.